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We read with interest the comments from Craig et al. [1] re-
garding our recently published clinical practice guidelines
for pharmacogenomic testing in anthracycline-based cancer
treatment [2]. Craig et al. [1] speciﬁcally posit that a func-
tional and mechanistic understanding of pharmacogenomic
associations is required prior to the issuance of clinical prac-
tice guidelines.
RARG rs2229774 (S427 L), SLC28A3 rs7853758 (L461 L)
and UGT1A6 rs17863783 (V209 V) have been shown to be
signiﬁcantly and strongly associated with anthracycline-in-
duced cardiotoxicity in three independent well-character-
ized paediatric patient populations [3–5]. The overall
strength of the pharmacogenomic associations (P-values
and odds ratios [OR: effect sizes] with 95% conﬁdence
intervals [CIs]) were as follows: RARG rs2229774 –
P = 5.9 × 108, OR (95%CI) = 4.7 (2.7–8.3); SLC28A3
rs7853758 – P = 1.6 × 105, OR (95%CI) = 0.36 (0.22–0.60);
and UGT1A6 rs17863783 – P = 2.4 × 104, OR (95%CI) = 4.30
(1.97–9.36) [3–5].
Functional studies of RARG rs2229774 have tied this vari-
ant to dysregulation of topoisomerase IIb, in line with the
role of TOP2B in anthracycline-induced cardiotoxicity [3, 6,
7]. As pointed out by Craig et al. [1] , UGT1A6 and SLC28A3
may not be expressed in the heart. However, the robustness
of these associations suggests that they exert at least indirect
effects on cardiac tissue, possibly through anthracycline bio-
transformation in other tissues. Notably, UGT1A6
rs17863783 (V209 V) is a variant in the UGT1A6*4 haplotype
that has been shown to have reduced (30–100%)
glucuronidation activity in vitro [8–10], linking this variant
to impaired drug metabolism. Anthracycline metabolites un-
dergo glucuronidation and a reduction in this metabolic step
may lead to accumulation of reactive oxygen species and
toxic alcohol metabolites [11, 12]. The SLC28A3 rs7853758
variant is suggested to be a cis-expression quantitative trait lo-
cus for this drug transporter, which is broadly selective for an-
ticancer drugs and contributes to the inﬂux of anthracyclines
in cancer cell lines [13]. The L461L minor allele has been
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associated with reduced SLC28A3 expression in multiple cell
lines [14, 15], which may therefore reduce cardiac cell expo-
sure to anthracyclines and hence exert its protective effect.
Despite the robust pharmacogenomic associations that
have been demonstrated as well as replicated, we agree that
studies in additional cohorts, including patients of different
ancestries, would be helpful in developing a more fulsome
understanding of all the genomic predictors of
anthracycline-induced cardiotoxicity and protection against
this serious adverse drug reaction. As Craig et al. [1] point
out, anthracycline treatment remains one of the most impor-
tant therapeutic options for a variety of paediatric cancers.
We recognize, that for clinicians, the primary focus is the ef-
ﬁcacy and cure rates in cancer patients. However, a signiﬁcant
proportion of patients are affected by this devastating and
life-threatening adverse effect and, as such, it is imperative
to balance the beneﬁts of treatment against the risks of toxic-
ity. It is important to note that our current recommendations
do not specify dose reductions (until such time as trials are
done to compare both toxicity and drug effectiveness at vary-
ing doses) and the recommendations explicitly advocate for
adherence to the current standards of care [2]. We recom-
mend low-risk therapeutic options that include increased
screening frequency for cardiotoxicity and monitoring for
cardiovascular diseases such as portal vein thrombosis, hyper-
tension, diabetes, hypercholesterolaemia, dyslipidaemia,
atrial ﬁbrillation, myocardial infarction and hypolipidaemia.
As studies are conducted to determine how best to ensure
anthracycline effectiveness while minimizing harm, these
clinical practice guidelines, like all guidelines, should be re-
vised as new evidence mounts. The challenge with the treat-
ment of any population of patients with severe disease is to
ensure that human variability in response (both harm and ef-
fectiveness) is studied more robustly to better understand
what is best for each patient and not assume that all patients
should be treated in the same way. This is not in contrast to
current population-based treatment approaches as both such
trials and precision medicine trials can and should co-exist. It
is not just new drug discovery that has resulted in sub-
stantive gains in cancer survivorship, but also improved use
of existing agents. With the discovery of robust phar-
macogenomic associations for treatment-related adverse
effects, however, there is also an ethical quandary of when
to act. Speciﬁcally, there is a reasonable ethical concern that
not acting on robust results such as these is not in keeping
with the best interests of the patients where the severity of
the adverse drug reaction can be fatal.
In summary, we have reported on existing functional and
mechanistic work to understand how anthracyclines cause
cardiotoxicity and the relationship to existing genomic ﬁnd-
ings. We agree wholeheartedly that additional mechanistic
understanding of the identiﬁed associations will enhance
the utility of the pharmacogenomics of adverse drug reac-
tions and this is an ongoing focus of our research. Through
international collaborations, we and others are studying
patient-speciﬁc stem-cell derived cardiomyocytes to assess
genotype–phenotype relationships related to anthracycline
cardiotoxicity. The validity of these pharmacogenomic asso-
ciations is strengthened by their robustness and replication
to a degree that justiﬁes inclusion in a clinical practice guide-
line that summarizes the evidence and highlights at the same
time the speciﬁc need for additional evidence [2]. The level of
evidence ascribed to each variant in these guidelines was gen-
erated in accordance with the Grading of Recommendations
Assessment, Development and Evaluation working group
guidelines [16, 17]. This in turn led to therapeutic recommen-
dations such as increased frequency of monitoring and ag-
gressive screening and management of cardiovascular
diseases as these are options where the beneﬁts of
pharmacogenomic screening clearly outweigh risks of the
speciﬁc recommendations.
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